Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Vascularized nerve grafts: an experimental study.
Peculiarities of Neurological Disorders and Study Designs.
Regional differences in interhemispheric structural fibers in healthy, term infants.
Comparison of two quantitative proton density mapping methods in multiple sclerosis.
What is the future of proof of concept studies in multiple sclerosis?
Galectin-1 circumvents lysolecithin-induced demyelination through the modulation of microglial polarization/phagocytosis and oligodendroglial differentiation.
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis.
Risk of Premenopausal and Postmenopausal Breast Cancer among Multiple Sclerosis Patients.
>CME/CNE ARTICLE: Severity Grading in Multiple Sclerosis: A Proposal.
Patterns of white matter damage are non-random and associated with cognitive function in secondary progressive multiple sclerosis.
Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
A family with hereditary diffuse leukoencephalopathy with spheroids caused by a novel c.2442+2T>C mutation in the CSF1R gene.
Comparative Analysis for the Presence of IgG Anti-Aquaporin-1 in Patients with NMO-Spectrum Disorders.
Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset.
The impact of drugs for multiple sclerosis on sleep.
ST8SIA2 promotes oligodendrocyte differentiation and the integrity of myelin and axons.
Monoclonal Antibody Therapy for Neuromyelitis Optica Spectrum Disorder: Current and Future.
Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark.
Astrocyte-mediated infantile-onset leukoencephalopathy mouse model.
Behavioral and electromyographic assessment of oxaliplatin-induced motor dysfunctions: Evidence for a therapeutic effect of allopregnanolone.
midamor: Uses, Dosage, Side Effects
Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap.
Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself.
Disability-Specific Atlases of Gray Matter Loss in Relapsing-Remitting Multiple Sclerosis.
Immunological treatment of multiple sclerosis.

Pages